Public Companies
Seelos Downgraded After Phase 2 Trial Failure
Cantor Fitzgerald, in reaction to the news, downgraded the stock.
The post Seelos Downgraded After Phase 2 Trial Failure appeared first on Green Market…
After an unfavorable outcome in a clinical trial, Seelos Therapeutics Inc. (Nasdaq: SEEL) saw its stock price plummet on Wednesday, falling 70% after news. Thursday continued the downward trend during pre-market trading after Cantor Fitzgerald downgraded the stock.
SLS-002, the company’s investigational psychedelic therapy, was aimed at alleviating suicidal symptoms in adults diagnosed with major depressive disorder. However, the 147-patient Phase 2 trial failed to achieve meaningful signals for its primary endpoint.
Financial constraints, which led to a failure in meeting the enrollment target, were cited by Seelos as the primary reason for the trial’s setback.
Charles Duncan, a Cantor analyst, subsequently downgraded Seelos from “Overweight” to “Neutral.” Duncan pointed out that the company’s financial limitations could obstruct its ability to effectively conduct and complete such trials in the future.
Furthermore, given the uncertainties concerning the regulatory response to the data, which might be addressed in a forthcoming meeting with the Food and Drug Administration, Duncan chose a conservative approach. He’s opted to remain neutral and has suspended his previous $2 per share target price.
The post Seelos Downgraded After Phase 2 Trial Failure appeared first on Green Market Report.
psychedelic trading nasdaq seelos therapeutics seelos-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials
-
Psilocybin1 week ago
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd